Patents Issued in December 24, 2020
  • Publication number: 20200399286
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Publication number: 20200399287
    Abstract: A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m2 or greater at a wavelength of approximately 400-700 nm to produce a color change.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 24, 2020
    Inventors: Pui Keong CHOW, Faan Fung HUNG, Chenmin LIU, Chi Ho KWOK
  • Publication number: 20200399288
    Abstract: The present invention relates to 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: December 4, 2018
    Publication date: December 24, 2020
    Inventors: Laurent Provins, Hugues Chanteux
  • Publication number: 20200399289
    Abstract: An aromatic compound which improves emission efficiency and an organic electroluminescence device including the same are provided. The organic electroluminescence device includes: a first electrode; a second electrode opposite to the first electrode; and a plurality of organic layers between the first electrode and the second electrode, where at least one organic layer among the plurality of organic layers includes the aromatic compound. The aromatic compound is represented by Formula 1 below.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Heechoon Ahn, Soo-byung Ko, Mieun Jun, Sungbum Kim, Mina Jeon, Youngkook Kim, Seokhwan Hwang
  • Publication number: 20200399290
    Abstract: A nanocomposite containing azole modified hollow silica spheres. In particular, the nanocomposite involves a silanization reaction product of an azole-functionalized silane linker and hollow silica spheres. The azole-functionalized silane linker is produced via a ring-opening reaction a silane coupling agent having an epoxide group and an azole compound. A method of making the nanocomposite is also specified.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 24, 2020
    Applicant: Imam Abdulrahman Bin Faisal University
    Inventors: Sarah Mousa M. ASIRI, Ayhan Bozkurt
  • Publication number: 20200399291
    Abstract: A method of making an aminosilane, the method comprising: forming a reaction mixture comprising a hydridosilane, an amine and a dehydrogenative coupling catalyst in a reactor; subjecting the reaction mixture to conditions sufficient to cause a dehydrogenative coupling reaction between the hydridosilane and the amine to form the aminosilane and hydrogen gas; and venting the hydrogen gas; wherein the forming of the reaction mixture comprising the hydridosilane, the amine and the dehydrogenative coupling catalyst comprises continuously feeding the hydridosilane to the reactor containing the amine and the dehydrogenative coupling catalyst.
    Type: Application
    Filed: February 13, 2019
    Publication date: December 24, 2020
    Inventors: Anthony E. Foss, Jesse A. Maddock, Brian D. Rekken, Michael D. Telgenhoff
  • Publication number: 20200399292
    Abstract: The present invention provides a composition for substrate surface modification and a method using the same, and the composition for substrate surface modification is composed of a compound of the general formula structure shown in formula 1: formula 1, wherein n1 is an integer of 1 to 6, and R is a zwitterionic group. The composition for substrate surface modification uses water as a medium to perform modifying reaction over a substrate surface, and at the same time has biological modification characteristics, and abilities of immobilizing biomolecules and anti-biofouling.
    Type: Application
    Filed: September 3, 2020
    Publication date: December 24, 2020
    Inventors: Chen-Han HUANG, Wen-Hao CHEN
  • Publication number: 20200399293
    Abstract: The present invention provides a composition for substrate surface modification and a method using the same, and the composition for substrate surface modification is composed of a compound of the general formula structure shown in formula 1: formula 1, wherein n1 is an integer of 1 to 6, and R is a zwitterionic group. The composition for substrate surface modification uses water as a medium to perform modifying reaction over a substrate surface, and at the same time has biological modification characteristics, and abilities of immobilizing biomolecules and anti-biofouling.
    Type: Application
    Filed: September 3, 2020
    Publication date: December 24, 2020
    Inventors: Chen-Han Huang, Wen-Hao Chen
  • Publication number: 20200399294
    Abstract: A process comprising: (a) contacting a feed stream comprising a di-alkyltin dihalide distillate with an alkylation agent, thereby forming an alkylated mixture comprising R4Sn and optionally R3SnX, R2SnX2, or mixtures thereof, where R is a linear, branched or cyclic C1-C20 alkyl, and X is a halide; (b) contacting the alkylated mixture with SnX4, thereby forming an alkyltin halide mixture comprising RSnX3, R2SnX2, and optionally impurities, R3SnX or mixtures thereof; (c) separating by distillation the alkyltin halide mixture to form a mono-alkyltin halide-rich distillate stream and a liquid di-alkyltin halide-rich bottoms stream comprising R2SnX2, RSnX3, and optionally impurities, R3SnX, or mixtures thereof; (d) separating by distillation the di-alkyltin halide-rich bottoms stream, thereby forming the liquid di-alkyltin dihalide distillate comprising R2SnX2, and optionally RSnX3, R3SnX or mixtures thereof, and an impurities-rich bottoms stream; and (e) recycling a part, xrecycle, of the liquid di-alkyltin di
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Peter FRENKEL, Joseph SALSBURY, Steven McKEOWN
  • Publication number: 20200399295
    Abstract: The invention provides a compound of formula (I) wherein B is a nucleobase; U is O or S; Rx is —OC(?O)Ry, —OC(?O)CH(Ry)NH2, —OCH2OC(?O)Ry; Ry is optionally substituted alkyl or alkenyl or the side chain of a natural or unnatural amino acid R1 is H, or optionally substituted phenyl, benzyl, naphthyl, pyridyl or indolyl, or Rx and R1 together define a bond thus forming a cyclic phosphate; R2 and R2? together define the side chain of a natural or unnatural amino acid; R3 is optionally substituted alkyl, cycloalkyl, phenyl or benzyl; and pharmaceutically acceptable salts and compositions thereof which are useful in the treatment of cancer, especially leukemias.
    Type: Application
    Filed: March 8, 2019
    Publication date: December 24, 2020
    Inventors: Björn KLASSON, Fredrik ÖBERG
  • Publication number: 20200399296
    Abstract: A non-aqueous electrolytic solution includes a phosphoric acid diester salt, which can suppress deterioration of charge-discharge characteristics of a power storage element, and can suppress the rise in internal resistance after storage at high temperature. The phosphoric acid diester salt is represented by the following chemical formula (1): in which Mn+ represents a hydrogen ion, an alkali metal ion, an alkali earth metal ion, an aluminum ion, a transition metal ion, or an onium ion, R1 and R2 are different from each other and represent a hydrocarbon group having 1 to 10 carbon atoms, or a hydrocarbon group having 1 to 10 carbon atoms and having at least one of a halogen atom, a heteroatom, and an unsaturated bond, and n represents a valence.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: Toshitaka SAKAGUCHI, Sojiro KON, Yoshifumi KATSURA, Masashi YAMAMOTO, Tetsuo NISHIDA
  • Publication number: 20200399297
    Abstract: Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 24, 2020
    Inventors: CAMPBELL MCINNES, SANDRA NAVONNE CRAIG
  • Publication number: 20200399298
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Publication number: 20200399299
    Abstract: Described herein are catalytic hydrogenation processes, using Ru complexes with tetradentate ligands of formula L in hydrogenation processes for the reduction of ketone, aldehyde, ester, or lactone into the corresponding alcohol or diol respectively. These processes use a ruthenium complex of formula (1) as defined herein.
    Type: Application
    Filed: March 12, 2019
    Publication date: December 24, 2020
    Inventors: Philippe DUPAU, Lucia BONOMO, Laurent KERMORVAN, Murielle HALDIMANN SANCHEZ
  • Publication number: 20200399300
    Abstract: Organometallic compounds useful in chemical phase deposition processes such as atomic layer deposition (ALD) and chemical vapor deposition (CVD).
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Applicant: SEASTAR CHEMICALS ULC
    Inventors: Rajesh ODEDRA, Cunhai DONG, Shaun CEMBELLA
  • Publication number: 20200399301
    Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 24, 2020
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Hong-Woon YANG
  • Publication number: 20200399302
    Abstract: This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.
    Type: Application
    Filed: January 27, 2020
    Publication date: December 24, 2020
    Inventors: Philip G. Haydon, Jinbo Lee
  • Publication number: 20200399303
    Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 24, 2020
    Inventors: Andrew W. FRALEY, Steven ROBINETTE, Nessan BERMINGHAM, Mallikarjuna Reddy PUTTA
  • Publication number: 20200399304
    Abstract: Disclosed herein are spherical nucleic acids (SNAs) comprising oligonucleotides comprising one or more modified oligonucleotides, and methods of use thereof. Also disclosed are methods of synthesizing modified oligonucleotides for use in therapeutics, including deoxynucleic guanidine (DNG)-modified oligonucleotides.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 24, 2020
    Inventors: Chad A. Mirkin, Kacper Skakuj, Katherine E. Bujold
  • Publication number: 20200399305
    Abstract: To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.
    Type: Application
    Filed: March 4, 2019
    Publication date: December 24, 2020
    Applicant: The University of Tokyo
    Inventors: Yasuteru URANO, Mako KAMIYA, Kento HAYASHI
  • Publication number: 20200399306
    Abstract: The present disclosure relates to solid phase synthesis of organic molecules and particularly to highly efficient methods for synthesizing polymers, such as peptides, nucleotides or saccharides, employing solid phase synthesis.
    Type: Application
    Filed: March 12, 2019
    Publication date: December 24, 2020
    Inventors: Chaim GILON, Moshe BENTOLILA
  • Publication number: 20200399307
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Hui F. LIU, Brian David KELLEY, Deanna E. MYERS, Beth MCCOOEY, Krista Marie PETTY
  • Publication number: 20200399308
    Abstract: Non-antimicrobial compounds, methods and compositions comprising the same for treating medical conditions associated with pathogenic microorganism in a subject, as well as drug-resistant strains thereof, which are effective in immunopotentiating the pathogenic microorganism to the antimicrobial systems in the subject, and/or act in synergism with exogenous antimicrobial drugs.
    Type: Application
    Filed: March 2, 2018
    Publication date: December 24, 2020
    Applicant: Technion Research & Development Foundation Limited
    Inventor: Amram MOR
  • Publication number: 20200399309
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20200399310
    Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).
    Type: Application
    Filed: May 13, 2020
    Publication date: December 24, 2020
    Inventors: Eun Seok Gil, Karl Gilbert, Manav Mehta
  • Publication number: 20200399311
    Abstract: The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 24, 2020
    Inventors: Mukul JAIN, Suresh GIRI, Rajesh BAHEKAR, Cupta GAURAV, Rajendra CHOPADE
  • Publication number: 20200399312
    Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.
    Type: Application
    Filed: March 2, 2020
    Publication date: December 24, 2020
    Inventors: Donald F. HUNT, Andrew NORRIS, Ann Michelle ENGLISH, Jeffrey SHABANOWITZ, William H. HILDERBRAND, Oriana E. HAWKINS
  • Publication number: 20200399313
    Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
    Type: Application
    Filed: March 2, 2020
    Publication date: December 24, 2020
    Inventors: William Jia, Xuexian Bu, I-Fang Lee
  • Publication number: 20200399314
    Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 24, 2020
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • Publication number: 20200399315
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 24, 2020
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Publication number: 20200399316
    Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Publication number: 20200399317
    Abstract: The template-fixed ?-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for where cancer is mediated or resulting from CXCR4 receptor activity
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Applicants: UNIVERSITAET ZUERICH, POLYPHOR LTD.
    Inventors: Daniel OBRECHT, Frank GOMBERT, Steven J. DEMARCO, Christian LUDIN, Jan Wim VRIJBLOED, Kerstin MOEHLE, John-Anthony ROBINSON, Reshmi MUKHERJEE, Heiko HENZE, Barbara ROMAGNOLI
  • Publication number: 20200399318
    Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.
    Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
  • Publication number: 20200399319
    Abstract: The disclosure provides a class of pH-sensitive, helix/random conformation switchable antimicrobial polypeptide (HRS-AMP) compositions as a single agent to selectively kill bacteria (e.g., H. pylori) under acidic condition in the stomach with diminished bacterial resistance compared to currently used antibiotics. Methods of treating bacterial infections in the stomach are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 24, 2020
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Jianjun Cheng, Lin-Feng Chen, Menghua Xiong, Yan Bao
  • Publication number: 20200399320
    Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
    Type: Application
    Filed: May 19, 2020
    Publication date: December 24, 2020
    Inventors: Jed J.W. WILTZIUS, Stuart A. SIEVERS
  • Publication number: 20200399321
    Abstract: The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 24, 2020
    Inventors: Aravind Asokan, Mavis Agbandje-McKenna, Long Ping Victor Tse, Brittney Gurda
  • Publication number: 20200399322
    Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Applicant: CureVac AG
    Inventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
  • Publication number: 20200399323
    Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Application
    Filed: December 11, 2018
    Publication date: December 24, 2020
    Inventors: Dan H. BAROUCH, Peter ABBINK, Mark Justin IAMPIETRO, Menzo J. E. HAVENGA
  • Publication number: 20200399324
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest, including microorganisms and plants. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Applicant: AGBIOME, INC.
    Inventors: Jessica Parks, Kira Bulazel Roberts, Rebecca E. Thayer
  • Publication number: 20200399325
    Abstract: A eukaryotic host cell engineered to produce a heterologous protein of interest (POI), which cell is genetically modified to reduce production of at least one of three different endogenous host cell protein (HCP), and its use in a method of producing the POI.
    Type: Application
    Filed: January 30, 2019
    Publication date: December 24, 2020
    Inventors: Katrien CLAES, James GRAHAM, Sylwia JOZWIAK, Christoph KIZIAK
  • Publication number: 20200399326
    Abstract: The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Penelope R. CHUA, Hanxiao JIANG, Adam Leon MEADOWS
  • Publication number: 20200399327
    Abstract: The present invention provides methods for treating or alleviating one or more symptoms of depression and/or anxiety in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject. The symptoms of depression and/or anxiety are typically observed in or associated with a neurological condition. The present invention also provides methods for treating a neurological condition such as a psychiatric disorder in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 24, 2020
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Huda AKIL, Stanley J. WATSON, Cortney TURNER
  • Publication number: 20200399328
    Abstract: Methods and compositions are provided for improved proteinaceous block copolymer fibers based on long repeat units having molecular weight of greater than about 10 kDal. Each repeat unit includes more than about 150 amino acid residues that are organized into a number of “quasi-repeat units.” The fibers have improved mechanical properties that better recapitulate those of the native silk fibers.
    Type: Application
    Filed: July 6, 2020
    Publication date: December 24, 2020
    Inventors: David BRESLAUER, Lindsay WRAY, Joshua KITTLESON
  • Publication number: 20200399329
    Abstract: The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 24, 2020
    Inventors: Niv BACHNOFF, Moshe COHEN-KUTNER
  • Publication number: 20200399330
    Abstract: This invention discloses isolated protein fractions from Apis mellifera royal jelly (RJ) have proven potent efficacy in inhibiting leukemia cell growth and HIV-1 reverse transcriptase (RT) as well as releasing the cellular sialic acid (sialidase catalytic activity). Methods for RJ fractionation, the investigation against leukemia cell lines (NFS-60 and Jurkat cells), HIV-1 RT, and cellular SA are disclosed.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 24, 2020
    Inventors: Salem Ismaell Salem EL-FIKY, Marwa Muhammad Abu-Serie ALI, Noha Hassan Habashy Mohammad ABD AL-GALIL
  • Publication number: 20200399331
    Abstract: Disclosed here are compositions comprising a curcuminoid-peptide complex. Also disclosed are methods of preparing a curcuminoid-peptide complex, comprising obtaining a curcuminoid; obtaining a peptide; and mixing the curcuminoid and the peptide in a solvent. Also disclosed are methods of treating a subject, the method comprising identifying a subject in need of treatment of a curcumin-related disorder, and administering to the subject a therapeutic composition comprising a curcuminoid-peptide complex as described. Also disclosed are therapeutic compositions comprising a curcuminoid-peptide complex as described and a pharmaceutically acceptable excipient, diluent, or carrier.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Applicants: Haus Bioceuticals, Inc.
    Inventors: Adam J. PAYNE, Michael CENTOLA, John CHANCEY
  • Publication number: 20200399332
    Abstract: The present invention relates to the provision of a recombinant AIM that maintains functions, does not multimerize, and is not inactivated by IgM (e.g., a protein containing an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and the like).
    Type: Application
    Filed: October 9, 2018
    Publication date: December 24, 2020
    Inventor: Toru Miyazaki
  • Publication number: 20200399333
    Abstract: Synthetic histatins composed of combinations of functional domains of natural histatins separated by exogenous linkers are described as are methods of using endogenous and synthetic histatins for the treatment of ocular diseases or conditions.
    Type: Application
    Filed: September 3, 2020
    Publication date: December 24, 2020
    Inventor: Vinay AAKALU
  • Publication number: 20200399334
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 24, 2020
    Inventors: Colette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • Publication number: 20200399335
    Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.
    Type: Application
    Filed: February 7, 2019
    Publication date: December 24, 2020
    Applicant: Aarhus Universitet
    Inventors: Martin Roelsgaard Jakobsen, Claus Elsborg Olesen